Posted inAllergy & Immunology Clinical Updates news
Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Crossover Trial and Related Evidence
This review synthesizes phase 3 RAPIDe-3 trial results demonstrating oral deucrictibant's rapid efficacy and safety for hereditary angioedema attacks, contextualized with phase 2 studies and prophylactic applications, highlighting its potential to transform management of bradykinin-mediated angioedema.